進階篩選

Technical category
技術研發單位
  • 共有:筆資料
  • 顯示:
  • 筆商品
    • Virus and Cell Culture Platform for Vaccine Production Technology

      Excellence Research Center FutureTech Virus and Cell Culture Platform for Vaccine Production Technology

      The "Viral Vaccine Cell Production Technology Platform" of this exhibition is based on 1. Host cell and virus match and colonization technology; 2. Cell-expressed virus receptor technology; 3. Blocking antiviral mechanism of host cell; 4. Immortalization technology of host cell; 5. Serum-free suspension cell culture technology to produce high-immunity virus vaccine strains containing intact virus antigens.
    • EditCell Virology Platform

      Excellence Research Center FutureTech EditCell Virology Platform

      1. Identification of host factor, which is required for virus replication, by “EditCell Virology Platform”. 2. The host factor will be as a target to develop antivirals. 3. The antiviral effects of the candidates can be validated in vitro and in vivo. 4. Two FDA-approved drugs are repurposed for COVID-19 treatment.
    • Antimicrobial peptide Epinecidin-1 promotes complete skin regeneration of methicillin-resistant Staphylococcus aureus-infected burn wounds in a swine model

      Precision Health Ecosystem FutureTech Antimicrobial peptide Epinecidin-1 promotes complete skin regeneration of methicillin-resistant Staphylococcus aureus-infected burn wounds in a swine model

      Chronic wound infection is a leading cause of mortality in injured patients worldwide. At present, available systemic antibiotic treatments have an insufficient tissue penetration ability and allow the development of antibiotic-resistant pathogens. The identification of therapeutic agents with wound healing and antimicrobial functions is necessary to heal the wound and cure infections. Our report shows that the antimicrobial peptide (AMP) Epinecidin-1 (Epi-1) efficiently heals MRSA-infected heat burn injuries and provides protection from infection in mouse and pig model. Our results demonstrate that the biomaterial Epi-1 heals wounds through increasing epithelial cell proliferation, vascularization, and the formation of collagen and controls MRSA infection-mediated sepsis in pigs.
    • Low-dose nanoscale biomimetic cell structure – Next-generation platform technology for advanced precision immunotherapy

      Precision Health Ecosystem FutureTech Low-dose nanoscale biomimetic cell structure – Next-generation platform technology for advanced precision immunotherapy

      We developed a biomimetic triple-antibody-immobilized magnetic fucoidan nanomedicine as a multifunctional artificial antigen presenting cell, which possessed the ability to not only inhibit immune checkpoint but activate tumor infiltrated T cells. of Bridging sites with tunable density on the nanoplatform was designed, allowing the antibodies to be well-distributed on the surface for mimicking immune cells. In contrast to the complex cell expansion process using microbeads in adaptive cell therapy, the nanoplatform can be i.v. administrated to cut the course of therapy from several weeks to days. With the development of the platform technology, an artificial immune system family can be built to pave the way for personalized immunotherapy.
    • A genomic marker guided roadmap to treat hepatocellular carcinoma

      Bio-tech & New Drugs FutureTech A genomic marker guided roadmap to treat hepatocellular carcinoma

      This is a method for identifying single nucleotide polymorphisms (GALNT14 genotypes) of a target nucleic acid for predicting whether a patient suffering from HCC will respond to combination chemotherapy. Accordingly, physicians can decide whether the HCC patients should receive chemotherapyTACE. This method could also predict prognosis in multiple gastrointestinal cancers.
本網站使用您的Cookie於優化網站。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。